Table 3.
Relationships between clinicopathological characteristics and PD-L1 expression in tumor-infiltrating immune cells
| Clinicopathological characteristics | Overall | PD-L1 (+) | PD-L1 (−) | Odds ratio (95% CI) | Global P |
|---|---|---|---|---|---|
| 378 | 152(40.2%) | 226(59.8%) | |||
| Age at diagnosis | 0.853(0.565–1.288) | 0.450 | |||
| ≥ 60 years | 188 | 72(38.3%) | 116(61.7%) | ||
| < 60 years | 190 | 80(42.1%) | 110(57.9%) | ||
| Gender | 1.205(0.707–2.055) | 0.494 | |||
| Male | 307 | 126(41.0%) | 181(59.0%) | ||
| Female | 71 | 26(36.6%) | 45(63.4%) | ||
| Tumor differentiation | |||||
| Well | 85 | 32(37.6%) | 53(62.4%) | 1 | |
| Moderate | 190 | 77(40.5%) | 113(59.5%) | 1.129(0.667–1.909) | 0.652 |
| Poor | 91 | 37(40.7%) | 54(59.3%) | 1.135(0.619–2.081) | 0.683 |
| Basaloid | 12 | 6(50.0%) | 6(50.0%) | 1.656(0.492–5.575) | 0.415 |
| Location | |||||
| Upper thoracic | 61 | 24(39.3%) | 37(60.7%) | 1 | |
| Middle thoracic | 209 | 71(34.0%) | 138(66.0%) | 0.793(0.441–1.428) | 0.440 |
| Lower thoracic | 108 | 57(52.8%) | 51(47.2%) | 1.723(0.911–3.260) | 0.094 |
| PT status | 1.211(0.760–1.931) | 0.421 | |||
| pT2 | 103 | 38(36.9%) | 65(63.1%) | ||
| pT3-4a | 275 | 114(41.5%) | 161(58.5%) | ||
| PN status | 1.630(1.286–2.067) | < 0.001 | |||
| pN0 | 189 | 53(28.0%) | 136(72.0%) | ||
| pN1 | 116 | 61(52.6%) | 55(47.4%) | ||
| pN2 | 52 | 26(50.0%) | 26(50.0%) | ||
| pN3 | 21 | 12(57.1%) | 9(42.9%) | ||
| Vascular invasion | 0.729(0.479–1.110) | 0.141 | |||
| No | 219 | 95(43.4%) | 124(56.6%) | ||
| Yes | 159 | 57(35.8%) | 102(64.2%) | ||
| Perineural invasion | 0.939(0.606–1.455) | 0.778 | |||
| No | 253 | 103(40.7%) | 150(59.3%) | ||
| Yes | 125 | 49(39.2%) | 76(60.8%) | ||
| Metachronous hematogenous metastasis | 0.989(0.574–1.707) | 0.969 | |||
| No | 313 | 126(40.3%) | 187(59.7%) | ||
| Yes | 65 | 26(40.0%) | 39(60.0%) | ||